SlidesetOncologyNew Designs for Early Clinical Trials of IO Drugs - Emiliano Calvo, Md, PhDView Slideset
SlidesetOncologyChanges and Challenges in Early Phase Trial Endpoints - Ruth Plummer, MDView Slideset
SlidesetOncologyLong Term Pemetrexed-based Cancer Treatment Leads to Nephrotoxicity - Nikki de RouwView Slideset
SlidesetOncologyPrediction of Capecitabine induced Severe Toxicity using Machine Learning Techniques - Maël SteunouView Slideset
SlidesetOncologyThe Long and Winding Road of the Clinical Introduction of a Biomarker - Jack Schalken, PhDView Slideset
SlidesetOncologyThe Use of Radiolabeled and Fluorescent Monoclonal Antibodies for Molecular Imaging in Oncology - Annelies Jorritsma-Smit, PharmD, PhDView Slideset
SlidesetOncologyEpigenetic Regulation of OCTN1-mediated Cytarabine Transport in Acute Myeloid Leukemia - Jason AndersonView Slideset
SlidesetOncologyComprehensive Pan-Cancer Analysis of Somatic Mutations in Drug Transporters to Reveal Acquired and Intrinsic Drug Resistance in 3149 Metastatic Cancer Patients - Wesley van de GeerView Slideset
SlidesetOncologyHow System Pharmacology Can Facilitate Clinical Drug Development in Oncology - Piet van der Graaf, PharmD, PhDView Slideset
SlidesetOncologyImpact of Immortal Time and Selection Bias on Exposure-response Modelling - Mats Karlsson, PhD, FCP, FISoPView Slideset
SlidesetOncologyClinical Pharmacology Strategy for Development and Labelling of New Medicine in the Era of Targeted Therapy and Accelerated Approvals in Oncology - Berges & SchalkwijkView Slideset
SlidesetOncologyPopulation Pharmacodynamics Modelling of Circulating Lymphocyte Count Over Time in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment - Fanny GallaisView Slideset
SlidesetOncologyPharmacokinetics and Safety of Pazopanib in Frail Elderly Patients - Félicien Le LouedecView Slideset
SlidesetOncologyEffects of Dietary Restriction in Cancer Patients Receiving Irinotecan - Ruben van EerdenView Slideset
SlidesetOncologyDose Individualization Potential for Oral Targeted Oncolytics - Neeltje Steeghs, MD, PhDView Slideset
SlidesetOncologyDose Individualization Potential for Checkpoint Inhibitors - Stijn Koolen, PharmD, PhDView Slideset
SlidesetOncologyInfluence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib - Koen HussaartView Slideset
SlidesetOncologyCorrelation Between Sunitinib Exposure and Toxicity in a Real-life Patient Cohort - Kim WesterdijkView Slideset
SlidesetOncologyDrug - Food Interaction an Unrealized Potential - Nielka van Erp, PharmD, PhDView Slideset
